Victoria Atkins has announced the use of emergency powers to ban the prescription of puberty blockers for new treatments of gender dysphoria from private clinics and for all purposes from overseas prescribers into Great Britain. This decision follows the Cass Review and aims to protect children. Suella Braverman supported the move, highlighting that children must not be placed on puberty blockers as a way of treating gender dysphoria and emphasizing the importance of child safeguarding over gender ideology. Under the new regulations, no new patients under 18 will be prescribed these medicines for the purposes of puberty suppression in those experiencing gender dysphoria or gender incongruence.
Countries are starting to ban child mutilation and puberty blockers. That’s great, but that’s not enough. I want the people who made this an acceptable practice to be outed and held accountable. How many kids have had their lives destroyed by these people? How much money…
Under the new regulations, no new patients under 18 will be prescribed these medicines for the purposes of puberty suppression in those experiencing gender dysphoria or gender incongruence. READ MORE: https://t.co/9MsjqAXTvS https://t.co/T8o9Z9pmTe
This is very welcome. I’ve met parents in Fareham whose children were put on puberty blockers, regretting it years later. Children must not be placed on puberty blockers as a way of treating gender dysphoria. Child safeguarding must always come first, not gender ideology. https://t.co/8u7LAJAVrc
Today I have taken bold action to protect children following the Cass Review, using emergency powers to ban puberty blockers for new treatments of gender dysphoria from private clinics and for all purposes from overseas prescribers into Great Britain. https://t.co/pLX7x0bH0n
The butchers and chemical castrators of children hiding behind compassion and fake expert consensus, pretending to follow the science as they destroy kids reproductive system and development with puberty blockers, will be judged in this life and the next.